Aseptic loosening is a major cause of failure of total hip arthroplasty. The adverse tissue response to prosthetic wear particles, with activation of cytokine and prostanoid production, contributes to bone loss around the implants. We have investigated the possibility that inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) are expressed in macrophages in the pseudomembrane at the bone-implant interface, thereby contributing to the periprosthetic bone resorption.
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Aseptic loosening is a major cause of failure of total hip arthroplasty. The adverse tissue response to prosthetic wear particles, with activation of cytokine and prostanoid production, contributes to bone loss around the implants. We have investigated the possibility that inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) are expressed in macrophages in the pseudomembrane at the bone-implant interface, thereby contributing to the periprosthetic bone resorption.
We also assessed whether peroxynitrite, a nitric oxide (NO)-derived oxidant associated with cellular injury, is generated in the membrane. Enzymatic activity of iNOS was measured using the arginine-citrulline assay technique and prostaglandin E 2 (PGE 2 ), as an indicator of COX-2 activity, was measured using an enzyme immunoassay.
Cellular immunoreactivity for iNOS, nitrotyrosine (a marker of peroxynitrite-induced cellular injury) and COX-2 was assessed by quantitative peroxidase immunocytochemistry while immunofluorescence methods were used for subsequent co-localisation studies with CD68 + macrophages.
The presence of calcium-independent iNOS activity and PGE 2 Aseptic loosening is a major clinical problem causing pain and the need for revision surgery. The pathophysiological mechanisms have yet to be defined although increasing evidence indicates that cyclic mechanical loading, production of prosthetic wear particles 1,2 and the ensuing adverse tissue response [3] [4] [5] are important contributors to local osteolysis and bone resorption at the bone-prosthesis interface. An interface membrane develops around the loosened prosthesis with a pseudosynovial layer adjacent to it. 1 Macrophages are predominant and epipolarised microscopy has shown that many are laden with wear particles. 2 The resultant cortical bone loss is considered to be caused by activation and release of a cascade of cell mediators by the pseudosynovial macrophages and other cells capable of phagocytosis of the prosthetic particulate debris. [3] [4] [5] Previous studies have established the expression in interface membranes of interleukin-1 (IL-1), tumour necrosis factor-␣ (TNF-␣) and the arachidonic-acid metabolite prostaglandin E 2 (PGE 2 ) which are strongly implicated in the induction and maintenance of bone resorption. [5] [6] [7] [8] [9] Cellculture experiments have confirmed the ability of isolated macrophages and pseudomembrane-derived cells to secrete IL-1, TNF-␣ and PGE 2 and to stimulate bone resorption, as a result of stimulation by wear particles. 3, 10, 11 Nitric oxide (NO) has now been shown to be one of the principal mediators of the actions of many cytokines and is known to induce PGE 2 production. [12] [13] [14] It is produced from a guanidino-nitrogen of L-arginine and dioxygen by three different isoforms of NO-synthases (NOS) arising from distinct genes. Two of these genes encode for endothelial and neuronal NOS (eNOS and nNOS), which are isoforms closely regulated by intracellular calcium levels and thought to be expressed constitutively. The third gene encodes for the inducible isoform of NOS (iNOS), expression of which is induced by many proinflammatory cytokines, including IL-1, TNF-␣ and interferon-␥ (IFN-␥), resulting in the production of large quantities of NO. This enzyme is also involved in modulating the activity of other key metabolic enzymes such as cyclo-oxygenase-2 (COX-2, prostanoid-converting enzyme), which is a primary target for non-steroidal anti-inflammatory drugs. Our studies and those of others have shown that NO functions as a second messenger molecule for many of the inhibitory actions of IL-1 and TNF-␣ on osteoblast activity 15, 16 COX-2 mRNA, protein and enzyme activity are up-regulated by IL-1 and TNF-␣ and, in some instances, NO has been implicated in the regulation of the COX-2 pathway. 13, 14, 17 Prototypic inhibitors of NOS activity have been shown to have a significant effect on the suppression of chronic inflammation and local bone destruction in experimental rat models of arthritis, 18, 19 and the possible involvement of NO in rheumatoid arthritis has been well documented. [20] [21] [22] [23] These findings suggest a role for NO in both acute and chronic inflammation and in the induction of bone destruction in such conditions. Other studies on osteoclast function and models of bone resorption, however, have suggested that it acts on osteoclasts in a biphasic manner regulating osteoclast motility and resorption activity and may have a preferential role as an inhibitor of bone resorption. 24, 25 NO is by definition a free radical, but it is not particularly reactive or toxic at relatively low levels, since it reacts with haemoglobin to form an inactive metabolite, methaemoglobin. At high levels, however, its cytotoxicity is much increased by its reaction with superoxide anion to form peroxynitrite. 26, 27 This causes oxidation of cell membrane lipids and DNA bases, thereby contributing to cell damage and injury, 26 and it has been implicated in a variety of clinical conditions, including rheumatoid arthritis, 21 atherosclerosis, 28 and adult respiratory distress syndrome.
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NO can inactivate superoxide dismutase leading to an increased accumulation of superoxide anion, which itself can stimulate bone resorption, and also interfere with the glutathione-glutathione peroxidase system resulting in an increased production of hydrogen peroxide, a reactive oxygen species able to activate bone resorption. 30 There is therefore considerable potential for cellular injury in diseases characterised by high-output NO production states. In this study, we hypothesise that the expression of iNOS and COX-2 is induced in activated periprosthetic macrophages associated with aseptic loosening and that peroxynitrite-induced protein nitrosylation can also be detected. This enzyme induction and the potential generation of NO, PGE 2 and peroxynitrite by wear-particle-stimulated macrophages may contribute to the aseptic loosening and eventual failure of total hip arthroplasties.
PATIENTS AND METHODS
Patients and tissue processing. Periprosthetic interface membranes were obtained at the time of revision surgery from ten patients with aseptic loosening, infection having been excluded (Table I ). There were five women and five * OA, primary osteoarthritis; CDH, secondary osteoarthritis due to congenital dislocation of the hip; RA, rheumatoid arthritis † A, both components; B, only acetabular cup; C, only prosthesis stem ‡ Co-Cr-Mo, cobalt-chromium-molybdenum alloy; Ti-Al-V, titanium-aluminium-vanadium alloy men with a mean age of 68 years (37 to 79). Eight of the total hip arthroplasties had originally been performed because of primary osteoarthritis, one for rheumatoid arthritis and one to treat secondary osteoarthritis caused by congenital dislocation of the hip. The mean time from primary arthroplasty to revision was 6.3 years (1 to 20). In the absence of obvious control tissue, mildly inflamed synovium from four patients with osteoarthritis, two with a suspected meniscal tear and three with patellar subluxation was obtained either at arthroscopy (n = 6) or during primary arthroplasty (n = 3) for comparative purposes. There were four women and five men with a mean age of 47 years (14 to 90). The tissues were either directly frozen for protein extraction or were fixed in fresh 1% paraformaldehyde made in 0.01 M phosphate-buffered 0.15 M saline solution (PBS, pH 7.1) by immersion for 16 to 18 hours at 4°C. After fixation, they were washed in PBS containing 15% (w/v) sucrose and 0.01% (w/v) sodium azide for 2 to 4 days at 4°C before mounting in cryoblocks and processing for immunocytochemistry. Measurement of NOS and COX enzyme activities in tissue homogenates. The tissues were homogenised in the presence of protease inhibitors (10 g/ml each of leupeptin, pepstatin A, bestatin, chymostatin; 12.5 g/ml soybean trypsin inhibitor; 100 g/ml phenylmethylsulfonyl fluoride (PMSF) (all Sigma, Poole, UK) and centrifuged (15 000 g) for three minutes. NOS activity in the homogenates was measured by conversion of [ BDH, Poole, UK), calmodulin (10 U/ml) and CaC1 2 (10 M). Calcium-independent iNOS activity was determined using the same reaction mixture, but with the addition of ethylenediaminetetra-acetic acid (EDTA; 2 mM; BDH) as a calcium-chelating agent, in the absence of CaC1 2 and calmodulin. N G -nitro-L-arginine-methyl ester (L-NAME; 1 mM), a prototypic inhibitor of NOS activity, was used to verify that specific NOS activity had been measured. After incubation for 30 minutes at 37°C, the conversion of [ Samples were centrifuged and 50 l aliquots of the supernatants were applied to thin-layer chromatographic plates (Merck silica gel 60, BDH) together with arginine and citrulline standards. After chromatographic separation (using chloroform: methanol: 17% ammonium hydroxide in the proportions of 40:40:20), the locations of the aminoacid standards were determined by spraying the plate with ninhydrin reagent. The sites corresponding to arginine and citrulline were removed for subsequent 
RESULTS

NOS activity and PGE 2 production. Conversion of [ 3 H]-
L-arginine to [ 3 H]-L-citrulline was used to study the NOS isoenzymes and their relative activity. The results showed that NOS enzyme activities were found at similar levels in both inflammatory conditions (pseudosynovium 0.945 ± 0.072 v osteoarthritic/traumatic synovium 0.994 ± 0.118 pmol/mg/min; p > 0.05). L-NAME reduced the activity by more than 95% (p < 0.01) confirming that authentic NOS enzyme activity was measured in the homogenates. Addition of the calcium-chelating agent EDTA into the reaction mixture was used for the evaluation of the relative amount of calcium-independent (iNOS) and calcium-dependent (eNOS and nNOS) enzyme activities. The results showed that 89% of the NOS enzymatic activity was calciumindependent (p < 0.01; Fig. 1 Figs 2a and 2b) . A small number of elongated fibroblast-like cells in the proximity of the synovial lining layer and in the stroma were strongly labelled using antisera raised against the iNOS and COX-2 peptide sequences. It was of special interest that both macrophageand fibroblast-like cells immunoreactive for iNOS and COX-2 were usually laden with prosthesis wear debris ( Figs  2c and 2d ), but cells heavily laden with particulate debris were usually negative for both iNOS and COX-2, presumably implying the cytotoxic effect of the wear debris and NO production. Vascular smooth muscle cells confined to small-calibre arterioles and venules and occasional endothelial cells were found to show iNOS and COX-2 immunoreactivity, in addition to many moderately labelled capillaries near the prosthesis interface lining. The number of iNOS-immunoreactive cells was higher in the interface membrane than in the osteoarthritic/traumatic synovium used as a control (29. , respectively. Statistical analysis by regression analysis confirmed a highly significant correlation between Fig. 1 Histogram showing the total, iNOS and constitutive calcium-dependent NOS (cNOS) enzyme activities in interface membrane homogenates from patients with aseptic loosening as determined by the citrulline assay and calcium chelation with 2 mM EDTA.
iNOS and CD68 + macrophages, COX-2 and CD68 + macrophages, nitrotyrosine and iNOS and COX-2 and iNOS (Fig.  4) . Double immunolabelling using the immunofluorescence technique showed unequivocally that iNOS and COX-2 were mostly localised in CD68 + macrophages (Fig. 5) . It also showed that in most cells nitrotyrosine was co-localised with iNOS, although in some cases strong immunoreactivity was also observed in other inflammatory and resident cells (Fig. 5) , suggesting peroxynitrite-induced protein nitrosylation and cellular damage not only in NO-producing cells but also in their neighbouring cells.
DISCUSSION
We have investigated the possibility that iNOS and COX-2 are induced in the interface membrane between the prosthesis and periprosthetic bone in patients with aseptic loosening. Such a process would provide a mechanism for wear-particle and cytokine-induced aggravation of local inflammation, bone resorption and prostanoid-induced pain, characteristic of the failure of total hip arthroplasty. Our results show that iNOS and COX-2 proteins and the corresponding enzyme activities are present in the interface tissue and that CD68 + macrophages are the major inflammatory cells expressing immunoreactivity for iNOS, nitrotyrosine and COX-2. This suggests that both iNOS and COX-2 pathways may be directly involved in aseptic loosening. Photomicrographs illustrating immunoreactivity for iNOS (A, brown) and COX-2 (B, brown) in the interface membrane from a patient with aseptic loosening (peroxidase technique). Many of the cells positive for iNOS and COX-2 contained wear-particle debris (C, epi-illumination technique, same section as shown in A). Cells which were heavily laden with debris (D, green colour shows debris, brown colour shows immunoreactivity for iNOS, superimposed image), however, showed no immunoreactivity for either iNOS or COX-2 (ϫ 300). Histogram showing the expression of iNOS and COX-2 immunoreactivity in synovium from nine patients with osteoarthritis or osteoarticular trauma (OA/trauma) and interface membrane from ten patients with aseptic loosening of a total hip replacement (THR), as determined by immunocytochemistry and the ratio between the total cells and those immunoreactive for iNOS or COX-2. Rodent macrophages produce high levels of NO, 12 but
information from experiments utilising human macrophages has indicated that conditions for cell priming in man may differ from those of rodents. 12, 31 Recent evidence suggests, however, that ligation of the human macrophage cell-surface molecule CD23 by monoclonal antibodies can result in the production of high concentrations of NO 31 and other studies from our laboratory have shown the presence of iNOS in macrophages associated with human atherosclerotic lesions. 28 This study provides evidence that prosthesis wear particles phagocytosed by macrophages found in the interface membrane of loosened total hip replacements are likely to contribute to the induction of iNOS by human macrophages. Calcium-independent iNOS enzymatic activity, as assessed by the conversion of [ 3 H]-L-arginine to [ 3 H]-L-citrulline, was found to be present in such tissues providing evidence that NO is also produced locally. Similar activity was seen in inflammatory synovium from patients with osteoarthritis or osteoarticular trauma, compatible with previous studies, 20 although fewer immunoreactive cells were observed. Further evidence of local NO (and superoxide) production, and peroxynitrite-induced oxidative damage, was provided by the localisation of nitrotyrosine in the interface membrane. It was found in cells immunoreactive for iNOS but also in neighbouring cells suggesting paracrine and cytotoxic effects of NO. The iNOS isoform is capable of producing large quantities of NO and of inducing COX-2 protein and prostanoid production. 13 In this study we used immunocytochemical techniques to investigate, at the cellular level on tissue sections, whether this mechanism would also apply to periprosthetic macrophages. Image-analysis quantification showed a significant correlation between iNOS and COX-2 tissue distribution and double immunolabelling of these two enzymes showed that both iNOS and COX-2 were found to a large extent in the same cells, namely CD68 + macrophages. Therefore it is possible that one pathway for COX-2 induction by cytokines synthesised and released during wear particle phagocytosis is NO-dependent. If high-output NO and peroxynitrite generation were to cause macrophage cell death this would result in the release of the phagocytosed wear debris. A detrimental cycle of events would then be established with further phagocytosis by newly-recruited inflammatory cells and subsequent NO, peroxynitrite and prostanoid synthesis. The presence of iNOS and COX-2, together with the evidence of peroxynitrite-induced cellular damage, provides the potential for possible future pharmacological intervention in the disease process. Selective drugs for clinical use which can suppress iNOS or COX-2 synthesis or enzyme activity, without interference with the constitutive isoforms of NOS and COX, may prove advantageous both in the suppression of chronic inflammation associated with aseptic loosening and in delaying the early failure of the prosthesis. Our previous studies have shown that IL-1-, TNF-␣-and IFN-␥-induced iNOS activity and high-output NO production result in inhibition of osteoblast proliferation and differentiation. 16 Furthermore, cytokine-induced NO synthesis is also involved in the induction of apoptosis, or programmed cell death, in osteoblast cultures. 32 Pitsillides et al 33 have shown that physiological levels of mechanical strain can induce NO production within a few minutes of application of the strain. This rapid NO production implies the presence of a constitutive form of NOS within the bone cells and our recent studies have indeed shown that eNOS isoform is present in osteoblasts, osteocytes and osteoclasts. 25, 34 It thus appears that NO may play a significant role during the early stages of mechanical strain-induced formation of new bone. 35, 36 It is therefore possible to speculate that low levels of NO, as produced by the constitutive calcium-dependent isoforms of NOS, may be important in the initial stages of bone-implant adaptation. Loading of the prosthesis and wear-particle generation, however, causes activation of inflammatory phagocytic cells, with the production of pro-inflammatory cytokines such as IL-1 and TNF-␣. The ensuing induction of iNOS and COX-2 with high-output production of NO, peroxynitrite and prostanoids would be detrimental to new bone growth, cause accelerated bone resorption and lead to aseptic loosening.
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Fig. 5
Immunolocalisation of iNOS (A, green) in CD68 + macrophage foci (B, red) shown as a superimposed image in C (yellow indicates co-localisation) in interface membrane from a patient with aseptic loosening. Nitrotyrosine immunoreactivity (D, green) was seen in many CD68
+ -positive cells (red; yellow indicates co-localisation) but also in neighbouring cells (double immunofluorescence labelling technique ϫ150).
